Catalog No. |
TD-HY403016 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG2-lambda |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
Extrinsic pathway inhibitor, Lipoprotein-associated coagulation inhibitor, TFPI, EPI, LACI, TFPI1, Tissue factor pathway inhibitor |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P10646 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Background |
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |